Begin forwarded message:
From: "New Medicine Oncology KnowledgeBASE"
<[EMAIL PROTECTED]>
Date: December 12, 2007 5:11:48 PM EST
Subject: Anticancer Drugs Targeting the ErbB (EGFr/HEr2) Pathway
Generated nearly $5 billion
Reply-To: "New Medicine Oncology KnowledgeBASE"
<[EMAIL PROTECTED]>
Anticancer Drugs Targeting the ErbB (EGFr/HEr2) Pathway Alone
Generated Global Sales of nearly $5 billion in the First Nine
Months of 2007
Currently, Over 370 Agents are in Active Clinical Development,
Addressing Over 190 Targets
LAKE FOREST, Calif., Nov. 27 /PRNewswire/ -- Six ErbB (EGFr/HEr2)-
pathway inhibitors, marketed for the treatment of several major
solid tumor indications, generated global sales of $4,964.4 million
in the first 9 months of 2007, almost surpassing the $5,160 million
total revenues of these agents in 2006.
Despite this unprecedented market success and the acceptance of
targeted therapies in oncology practice, many challenges remain
unfulfilled. One key problem of currently approved agents is the
relatively marginal benefits they provide; median progression-free
survival (PFS) and overall survival (OS) are extended only by a few
months. However, aggressive efforts to overcome current
limitations are providing unique opportunities in this field.
Currently, all targeted therapeutics, both approved and novel are
under evaluation almost exclusively in combination with approved
cytotoxic agents. Because cytotoxics remain the treatment mainstay
for adjuvant, neoadjuvant and advanced/metastatic disease,
opportunities still exist for the development of more effective,
less toxic alternatives.
Targeted therapeutics are also under investigation in combination
with each other, in efforts to simultaneously inhibit additional or
compensating pathways, or to maximize effectiveness against a
single target by combining drugs acting by different mechanisms,
e.g., receptor tyrosine kinase (RTK) inhibitors and monoclonal
antibodies (MAb), against the same target. Also, multitargeted
inhibitors are in development against different targets in the same
or different pathways hypothesized to act in concert in malignancy.
The commercial success of the ErbB inhibitors and other targeted
anticancer agents has stimulated R&D in this field. More than 370
drugs have entered clinical trials, with many having already
reached phase II (n=183) or phase III (n=43) stages of
development. In addition hundreds of agents are in preclinical
development. Their mechanisms of action are wide ranging,
targeting some of the more than 1,000 different molecular markers
implicated in malignancy.
Molecularly targeted agents in development are ushering in the age
of personalized medicine. There is pressing need for better
diagnostic, theragnostic, prognostic, pharmacogenomic and disease
monitoring methodologies for patient selection and optimized
treatment.
The source, mechanisms of action, and preclinical and clinical
status, including interim and final trial results, of all of these
agents are described in detail in New Medicine’s Oncology
KnowledgeBASE (nm/OK). By interrogating nm/OK users may:
• Identify novel agents addressing either a single target or
multiple pathways/targets and review in detail their preclinical
and clinical status
• Locate targeted agents in clinical trials in combination with
specific approved cytotoxic agents or classes of such drugs, i.e.
platinum-based agents, taxanes, etc.
• Obtain comprehensive, cited data on over 1,000 targets that may
be applicable as diagnostic, theragnostic, prognostic,
pharmacogenomic, disease monitoring and/or therapeutic targets in
cancer
• Obtain interim and final results of combination trials of
approved anticancer agents, by cancer indication, target, clinical
development status, etc.
• Obtain detailed records of anticancer targets by 100 different
cancer indications, and many subtypes such as non-small cell lung
cancer (nsclc), triple receptor-negative breast cancer,
glioblastoma multiforme (GBM), etc.
• View detailed records of drugs in development for several hundred
highly specific clinical indications, i.e. advanced or metastatic
disease, adjuvant or neoadjuvant treatment, first line or second
line treatment
• Obtain detailed preclinical and/or clinical pipelines of over
1,000 developers of anticancer agents, including detailed profiles
of the companies and their affiliates
• Identify licensing opportunities
• Assess global market opportunities based on revenues of approved
drugs and the epidemiology of specific cancer indications
• Create proprietary ‘saved searches’ to monitor developments in a
pre-selected group of agents chosen by specific shared parameters,
i.e., targets, delivery systems, mechanism of action, cancer
indication, clinical indication, stage of development, etc.
Contact us for an online demonstration of nm|OK.
Contact: Katie Siafaca
Tel: (949) 830-0448;
Fax: (949) 830-0887
E-mail: [EMAIL PROTECTED]
http://www.newmedinc.com
http://nmok.net
http://nmok.net/oksite/samprecords.html
SOURCE New Medicine's Oncology KnowledgeBASE
